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infusion: an updated systematic review and
meta-analysis
Takeshi Seta1,4, Yoshinori Noguchi2, Satoru Shikata3 and Takeo Nakayama4*Abstract
Background: The intravenous use of protease inhibitors in patients with acute pancreatitis is still controversial. The
purpose of this study was to evaluate the effectiveness of protease inhibitors intravenously administered to prevent
pancreatitis-associated complications.
Methods: We updated our previous meta-analysis with articles of randomized controlled trials published from January
1965 to March 2013 on the effectiveness of protease inhibitors for acute pancreatitis. A systematic search of PubMed,
EMBASE, the Cochrane Library, and Japana Centra Revuo Medicina was conducted. In addition, Internet-based registries
(ClinicalTrials.gov, controlled-trials.com, UMIN, JMACCT, and JAPIC) were used to search for on-going clinical trials.
Furthermore, references of review articles and previously published meta-analyses were handsearched. The main
outcome of interest was the overall mortality rate from acute pancreatitis.
Results: Seventeen trials were selected for analysis. Overall, protease inhibitors did not achieve a significant risk
reduction in mortality (pooled risk difference [RD], −0.02; 95% Confidence Interval [CI], −0.05 to 0.01; number
needed to treat [NNT], 74.8) with low heterogeneity. A subgroup analysis in moderate to severe pancreatitis
(defined by control mortality rate [CMR] >0.10) did not show a significant effect of protease inhibitors to prevent
death (pooled RD, −0.03; 95% CI, −0.07 to 0.01; NNT, 1603.9) with low heterogeneity. An additional subgroup
analysis of two trials with CMR >0.20 (i.e., low quality) revealed a significant risk reduction.
Conclusion: The present meta-analysis re-confirmed that there is no solid evidence that supports the intravenous
use of protease inhibitors to prevent death due to acute pancreatitis.
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Acute pancreatitis is characterized by sudden abdominal
pain and elevated serum concentrations of pancreatic en-
zymes. Overall mortality has been reported to be approxi-
mately 5 percent for acute pancreatitis and 20 percent
for necrotizing pancreatitis [1,2]. Mild acute pancreatitis
is generally treated with supportive care including pain
control, intravenous fluids, and correction of electrolyte
and metabolic abnormalities. A meta-analysis of eight trials* Correspondence: t-nakayama@umin.ac.jp
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reproduction in any medium, provided the orrevealed that enteral nutrition significantly reduced mortal-
ity, multiple organ failure, systemic infections, and the
need for surgery compared with parenteral nutrition [3].
Furthermore, other meta-analyses that have been con-
ducted on the effectiveness of acute pancreatitis treatments
showed that the use of suitable analgesics effectively re-
lieved pain [4], and that H2 receptor antagonists did not
improve clinical outcomes of acute pancreatitis [5].
The role of protease inhibitors in the treatment of
mild to severe acute pancreatitis is still unclear, although
previous studies have demonstrated a marginal reduc-
tion in mortality. In particular, continuous regional ar-
terial infusion of protease inhibitors was shown to be. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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servational studies [6-8], as well as in a randomized con-
trolled trial (RCT) [9]. In 2004, we conducted a meta-
analysis of 10 RCTs with a total sample size of 1,036 [10]
to evaluate the effectiveness of intravenous use of protease
inhibitors for acute pancreatitis. The main outcome
was the effectiveness of protease inhibitors to prevent
death due to acute pancreatitis, and secondary outcomes
were prevention of pancreatic pseudocyst, intra-abdominal
abscess, and surgical intervention. Our analysis re-
vealed no improvement in all outcomes. Moreover, prote-
ase inhibitors did not significantly reduce the mortality in
the trials with control mortality rate (CMR) equal to or
less than 0.10, but might reduce the mortality with CMR
more than 0.10.
The purpose of the present study was to update the
body of evidence on the effectiveness of intravenous use
of protease inhibitors for acute pancreatitis.
Methods
A systematic review of meta-analyses was conducted
and the results were described according to the PRISMA
statement [11].
Literature search
First, we systematically searched PubMed, EMBASE, the
Cochrane Library, and Japana Centra Revuo Medicina
(the largest database of Japanese articles) for articles of
RCTs published from January 1965 to March 2013 (search
date: April, 2013) on the effectiveness of protease inhibi-
tors used to treat acute pancreatitis. The electronic data-
base search was conducted using a combination of
Medical Subject Heading terms and text words “protease
inhibitors” and “acute pancreatitis”. Next, we searched
Internet-based clinical trial registries, ClinicalTrials.gov
[12] and controlled-trials.com [13], as well as all the three
trial registries available in Japan, UMIN [14], JMACCT
[15], and JAPIC [16] (search date: April, 2013) for on-
going RCTs using the same criteria. References of review
articles and previously published meta-analyses were
handsearched.
Inclusion and exclusion criteria
Given that the purpose of the present study was to update
the body of evidence regarding the effectiveness of intra-
venous use of protease inhibitors for acute pancreatitis,
the following inclusion criteria were set: 1) randomized
placebo-controlled trials of protease inhibitors adminis-
tered through intravenous infusion; and 2) written in all
languages. No restrictions were placed on severity of pan-
creatitis or type of protease inhibitors. Furthermore, we
excluded trials in which 1) both intervention and control
groups were administered protease inhibitors; 2) protease
inhibitors were administered by intra-arterial or intra-abdominal infusion; 3) subjects included patients with
chronic pancreatitis; 4) pancreatitis was noted after endo-
scopic retrograde cholangiopancreatography (ERCP); 5)
patients were administered frozen plasma; 6) the goal was
to investigate basic medical science (e.g., pancreatic en-
zyme research); 7) patients had human immunodeficiency
virus; 8) efficacy of antibiotics was being evaluated; 9) pa-
tients included post-operative cases; and 10) oral adminis-
tration of protease inhibitors.
No restrictions were placed on patient age, sex, or
cause of acute pancreatitis. Articles in the form of a con-
ference proceeding or full paper were also included. One
author (TS) selected articles to be included for analysis,
and the other authors verified the process.
Outcome measures
The effectiveness of protease inhibitors for acute pan-
creatitis was evaluated based on the primary outcome of
death due to acute pancreatitis, and secondary outcomes
including relief from pain, pseudocyst formation, forma-
tion of intra-abdominal abscess, surgical intervention,
paralytic small bowel obstruction, and other major com-
plications including multiple organ failure.
Study characteristics
Study design, participants, mode of intervention, and
definition of outcomes were faithfully extracted from the
articles included in the final analysis. We also confirmed
the status of industrial support for each trial.
Control mortality rate (CMR)
We calculated CMR (defined as the number of deaths in
the control group divided by the number of patients in
the control group) for each RCT.
Quality assessment for selected trials and data extraction
The quality of each trial retrieved was assessed by the
Jadad method [17] on the basis of whether the trial was
randomized, the appropriateness of the randomization
process (if applicable), whether the trial was double-
blinded, the appropriateness of the double-blinding
process (if applicable), and withdrawals/dropouts. Each
item was assigned a score of 0 or 1, and the total score
ranged from 0 to 5. In the present meta-analysis, trials
with a Jadad score greater than 3 were defined as high-
quality trials. Furthermore, we evaluated risk of bias for
each trial and assessed the quality of the body of evi-
dence using the Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) system
for grading evidence [18].
One author (TS) conducted the quality assessment
and extraction of analyzable data, which were verified by
the other authors. Disagreement or uncertainty was re-
solved among all the authors.
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We calculated the risk difference (RD), i.e., risk in the
intervention group minus risk in the control group, for
the primary outcome of the trials. A negative RD indicated
risk reduction due to intervention, and a positive RD, risk
increase due to intervention (range, −1 to 1). Whether the
treatment or control was favored was denoted by the
signs “+” and “-”, respectively. Then, the weighted pooled
estimates were calculated for binary data. A fixed-effect
model weighted by the Mantel-Haenszel (M-H) method
was used for pooling RD [19], followed by a test of homo-
geneity. Homogeneity among trials was assessed using the
I2 test [20]. We defined I2 value <25% as low, 25 to 50% as
moderate, and >50% as high heterogeneity.
If the hypothesis of homogeneity was rejected, a
random-effect model using the DerSimonian-Laird (D-
L) method was employed [21]. The potential for publica-
tion bias was examined by the funnel plot method [22]
using the Begg’s [23] or Egger’s test [24]. The number
needed to treat (NNT, 1/RD) to prevent one adverse
event was also used as a measure of treatment effect.
We used the “number needed to treat benefit (NNTB;
the number of patients needed to be treated for one
additional patient to benefit)” for a positive NNT, and
the “number needed to treat harm (NNTH; the number
of patients needed to be treated for one additional pa-
tient to be harmed)” for a negative NNT. When the
upper or lower limit of the 95% confidence interval (CI)
was infinity, the NNT scale including infinity was used
[25]. All statistical analyses were performed with Stata
statistical software [26]. Results were expressed as means
and 95% CIs, unless otherwise indicated. P < 0.05 was
considered statistically significant.
Results
Trial selection and features (Figure 1 and Additional file 1:
Table S1)
Our database search yielded 96 articles, and handsearch-
ing of bibliographies of retrieved meta-analyses and clin-
ical guidelines yielded additional three and two articles,
respectively. There were no on-going trials in the regis-
tries. Of the 101 articles, 24 met the inclusion criteria
[27-50]; no multiple publications were found. Reviewers’
selection of relevant articles was completely the same, and
there was no unsuitable study for inclusion by authors’
consensus. The 77 excluded articles described ERCP stud-
ies (n = 36), studies in which a protease inhibitor was
administered to both intervention and control groups
(n = 8), arterial infusion studies (n = 6), and other (n = 27)
(Figure 1). Next, all authors read the selected 24 articles,
reaching a consensus to exclude seven more articles
[27,38-40,45,48,50] including two in which a protease
inhibitor was administered to both intervention and con-
trol groups [30,45], two that were published as comments[38,50], one in which glucagon was given to the control
group [39], one published as an editorial (n = 1) [40], and
one reporting an ERCP study [48]. In the end, a total of 17
articles [27-29,31-37,41-44,46,47,49] were selected for
analysis.
The present meta-analysis of the retrieved competent
studies included 15 RCTs from the handsearch [27,28,
31-37,41-43,46,47,49], one [29] from a previous meta-
analysis [51], and one [44] from guidelines [52], with the
total sample size of 1,697 patients. Of the 15 articles
manually searched, 10 [33,34,37,41-44,46,47,49] were
used in our previous meta-analysis [10].
All articles evaluated death due to acute pancreatitis,
in addition to other outcomes such as pain relief (n = 2)
[31,49], pseudocyst formation (n = 5) [29,37,41,43,46],
intra-abdominal abscess formation (n = 4) [37,41,43,46],
surgical intervention (n = 3) [44,47,49], paralytic small
bowel obstruction (n = 3) [41,47,49], and other compli-
cations (n = 5) [36,37,43,46,47]. Of the 17 articles, 11
[29-31,33-36,41,42,44,46,47] were conducted in a multi-
center setting, and six [27,28,32,37,42,49] in a single-
center setting. Sixteen articles were published as a full
paper [27-29,31-37,41-43,46,47], and one as an abstract
only [44]. Fourteen articles were written in English
[27-29,31,33-35,37,41,43,44,46,47,49], two in German
[32,42], and one in French [36]. Eleven trials used apro-
tinin [27-29,31-37,41], and six trials used gabexate
mesilate [42-44,46,47,49], all against the placebo con-
trol. Four articles [36,41,47,49] described tangible out-
comes in the method section, whereas 13 provided no
description [27-29,31-35,37,42-44,46]. The sample size
was pre-calculated only in one article [47]. Acute pan-
creatitis was defined as clinical manifestation with ele-
vated serum pancreatic enzyme levels in 11 articles
[27-29,34,35,37,41,43,46,47,49], or as clinical manifest-
ation with elevated urine pancreatic enzyme levels in
two [32,33]; no description regarding the definition was
found in the remaining four articles [31,36,42,44]. Nine
articles described sources of funding or medicine sup-
port from industries [27,29,31,34,35,37,41-44]. The se-
verity of acute pancreatitis was reported using the
Ranson’s score in two articles [47,49], or Acute Patho-
physiology and Chronic Health Evaluation (APACHE-
II) score in one article [49]. In addition to these, we
evaluated the severity of acute pancreatitis according to
CMR in the present analysis, and found that 10 articles
had CMR >0.10 [27,28,34-36,41,43,44,47,49]. No arti-
cles mentioned the presence or absence of adverse
events. Seven articles observed death due to acute pan-
creatitis as the primary outcome [27,28,32-35,47]. Six
articles reported no secondary outcome [27,28,32-35],
while one article observed surgical intervention and
bowel obstruction as the secondary outcomes [47]. Ten
articles reported undistinguishable outcomes [29,31,36,
Figure 1 Flow of randomized controlled trials through the process of retrieval and inclusion in the meta-analysis comparing protease
inhibitors with placebo for acute pancreatitis. The numbers in parentheses are the ‘Jadad scores’ of the individual trials. 95% CI, 95%
confidence interval. ERCP, endoscopic retrograde cholangiopancreatography.
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ment and found death, pseudocyst, intra-abdominal ab-
scess, and any major complications to be low quality,
and abdominal pain, surgical intervention, and bowel
obstruction to be very low quality. Table 1 shows het-
erogeneity of each outcome with I2 values.
Quality assessment (Additional file 1: Table S1 and Table 2)
The overall mean Jadad score was 2.1 (range 0–5).
The mean Jadad score increased to 2.6 if three RCTs
with a 0 score [28,32,43] were excluded. Six trials [31,34,
35,37,46,47] were considered high quality (Jadad score
≥3), with the mean Jadad score of 3.7. With respect to
risk of bias of each trial, two described random alloca-
tion [46,47], 13 described allocation concealment [27,29,
31,33-37,41,42,44,46,47], 13 described blinding [27,29,31,
33-37,41,42,44,46,47], three described outcome data ad-
dressed [44,46,47], and four described selective outcome
reporting [36,41,47,49]; no other bias was described.
One RCT described intention to treat (ITT) analysis
[47]. The quality of each outcome in terms of evidence
was graded low to very low.
Primary outcome: preventing death (Tables 1 and 3)
All trials reported death due to acute pancreatitis
(Table 1 and Figures 2 and 3), 11 with aprotinin [27-29,
31-37,41], and six with gabexate mesilate [42-44,46,47,49].
Overall results of the 17 trials showed no significant risk
reduction (low heterogeneity) in mortality with the use of
protease inhibitors. Furthermore, subgroup analyses re-
vealed no significant results (Table 3).Secondary outcomes
Preventing abdominal pain
Two trials reported that protease inhibitors (aprotinin
[31] and gabexate mesilate [49]) were effective in pre-
venting abdominal pain [31,49]. Overall results showed a
significant risk reduction (high heterogeneity) with pro-
tease inhibitor use. However, the subgroup analysis of
one of the two trials deemed high quality [31] revealed
no significant effectiveness.
Preventing pseudocyst formation
Five trials (three for aprotinin [29,37,41] and two for gabex-
ate mesilate [43,46]) reported that protease inhibitors were
effective in preventing pseudocyst formation. Overall results
showed no significant risk reduction (low heterogeneity).
Preventing intra-abdominal abscess formation
Four trials (two for aprotinin [37,41] and two for gabex-
ate mesilate [43,46]) reported that protease inhibitors
were effective in preventing intra-abdominal abscess for-
mation. Overall results showed no significant risk reduc-
tion (low heterogeneity).
Preventing surgical intervention
Three trials, all of which evaluated the use of gabexate
mesilate, reported that the protease inhibitor was effect-
ive in preventing surgical intervention [44,47,49]. Overall
results showed a significant risk reduction (moderate to
high heterogeneity). However, the subgroup analysis of
one of the three trials deemed high quality [47] revealed
no significant effectiveness.
Table 1 Evaluation of evidence quality of using each RCT




Other bias ITT analysis
Skyring A [27] 1965 no yes yes no no no no
Ryall RJ [28] 1966 no no no no no no no
Trapnell JE [29] 1967 no yes yes no no no no
Bachrach WH [31] 1968 no yes yes no no no no
Möller C [32] 1969 no no no no no no no
Baden H [33] 1969 no yes yes no no no no
Trapnell JE [34] 1974 no yes yes no no no no
MRC Multicenter Trial [35] 1977 no yes yes no no no no
Gauthier A [36] 1978 no yes yes no yes no no
Imrie CW [37] 1978 no yes yes no no no no
MRC Multicenter Trial [41] 1980 no yes yes no yes no no
Freise J [42] 1986 no yes yes no no no no
Yang CY [43] 1987 no no no no no no no
Goebell H [44] 1988 no yes yes yes no no no
Valderrama R [46] 1992 yes yes yes yes no no no
Büchler M [47] 1993 yes yes yes yes yes no yes
Chen HM [49] 2000 no no no no yes no no
RCT randomozed controlled trial; ITT intension to treat.
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Three trials (one for aprotinin [41] and two for gabexate
mesilate [47,49]) reported that protease inhibitors were
effective in preventing bowel obstruction. Overall results
showed a significant risk reduction (moderate to high
heterogeneity). However, the subgroup analysis of one of
the three trials deemed high quality [47] revealed no sig-
nificant effectiveness.
Preventing major complications
Five trials (two for aprotinin [36,37] and three for gabex-
ate mesilate [43,46,47]) reported that protease inhibitors
were effective in preventing some complications. These
complications included respiratory failure, renal failure,
gastrointestinal bleeding, metabolic failure (details un-
known), sepsis, or hypoxia [43,46]. Three studies defined
complications as pancreatitis-related complications or
unknown [33,37,47]. Overall results showed no signifi-
cant risk reduction (low heterogeneity).
Publication bias (Figure 4)
The funnel plot was not symmetric; however, neither
one of the statistical tests revealed significant publication
bias (p = 0.653 and p = 0.736, respectively).
Sensitivity analysis for trial quality (Tables 4 and 5)
Using the main outcome, i.e., overall mortality from
acute pancreatitis, we performed a sensitivity analysis ac-
cording to the Jadad score. The effect size and level ofstatistical significance did not decrease with increasing trial
quality. We then performed another sensitivity analysis ac-
cording to CMR. In all trials and trials with CMR <0.20,
no significant effectiveness of protease inhibitors was
shown. However, a significant effectiveness was found
when trials were limited to those with CMR >0.20.
Discussion
In this study, we conducted a systematic review of RCTs
to update our previous meta-analysis of 2004 on the ef-
fectiveness of intravenous infusion of protease inhibitors
for acute pancreatitis. As the present literature search re-
trieved no additional RCTs since 2004 up to March 2013,
we analyzed a new set of articles including those that had
not been identified in the previous meta-analysis [10]. The
present analysis re-confirmed the validity of evidence
reported to date, as follows: 1) treatment with protease
inhibitors did not significantly reduce the mortality rate
from acute pancreatitis; 2) subgroup analysis of trials
with CMR greater than 0.20 showed limited effective-
ness of protease inhibitors in preventing death; 3) pro-
tease inhibitors showed no significant effectiveness
even in outcomes other than preventing death. More-
over, given that there are no on-going trials regarding
the use of protease inhibitors for acute pancreatitis, no
new evidence supporting their effectiveness is expected
to emerge for the next few years.
In the previous meta-analysis, we evaluated prevention
of death due to acute pancreatitis, formation of pancreatic
Table 2 Effectiveness for acute pancreatitis with protease inhibitors
Outcomes No. of
studies
Pooled risk difference NNT Heterogeneity Statistical method
by effect model
Quality of a
body of evidenceValue 95%CI Value 95%CI I2value(%)
Lower Upper NNTB NNTH
Death 17 -0.02 -0.05 0.01 74.8 NNTH 62.4 to ∞ to NNTB 23.4 0 M-H
low
High quality studies 6 -0.02 -0.06 0.02 624.6 NNTH 24.6 to ∞ to NNTB 26.7 34.1 M-H
Aprotinin 11 -0.01 -0.05 0.02 89.3 NNTH 38.8 to ∞ to NNTB 20.8 0 M-H
Gabexate mesilate 6 -0.02 -0.07 0.03 54.3 NNTH 33.3 to ∞ to NNTB 14.9 31.1 M-H
Daily dosage >900 mg of GM 5 -0.02 -0.09 0.04 55.2 NNTH 8.3 to ∞ to NNTB 14.C 47.0 M-H
Daily dosage >1500 mg of GM 2 -0.09 -0.33 0.15 33.6 NNTH 17.8 to ∞ to NNTB 8.6 79.0 D-L
Mild pancreatitis 7 0.00 -0.03 0.04 177.5 NNTH 24.5 to ∞ to NNTB 33.9 0 M-H
Moderate to severe pancreatitis 10 -0.03 -0.07 0.01 1604 NNTH 23.0 to ∞ to NNTB 23.7 19.7 M-H
Severe pancreatitis 2 -0.19 -031 -0.08 5.2 3.2 to 12.7 0 M-H
With sponsor 9 -0.02 -0.06 0.02 67.0 NNTH 43.0 to ∞ to NNTB 18.8 15.0 M-H
Without sponsor 8 -0.02 -0.06 0.03 68.4 NNTH 31.9 to ∞ to NNTB 16.5 0 M-H
Abdominal pain 2 -0.26 -0.40 -0.13 3.9 2.5 to 9.6 85.0 D-L
very low
High quality study 1 -0.14 -0.32 0.03 6.9 NNTH 30.1 to ∞ to NNTB 3.1 Uncalculatable M-H
Pseudocyst formation 5 -0.00 -0.05 0.03 298.6 NNTH 27.3 to ∞ to NNTB 23.1 0 M-H low
Intra-abdominal abscess formation 4 -0.01 -0.04 0.02 113.2 NNTH 65.3 to ∞ to NNTB 30.3 0 M-H low
Surgical intervention 3 -0.08 -0.17 -0.00 11.8 6.0 to 443.8 60.5 D0L
very low
High quality study 1 0.00 -0.10 0.11 225.8 NNTH 8.9 to ∞ to NNTB 9.7 Uncalculatable M-H
Bowel obstruction 3 -0.06 -0.12 -0.00 6.3 4.0 to 14.5 58.8 D-L
very low
High quality study 1 -0.03 -0.08 0.02 33.9 NNTH 44.2 to ∞ to NNTB 12.3 Uncalculatable M-H
Any major complications 5 -0.01 -0.08 0.06 76.4 NNTH 15.7 to ∞ to NNTB 11.1 0 M-H low


















Table 3 Subgroup analyses on the primary outcome (death due to acute pancreatitis)
No Subgroup Trial (n) Citations Effectiveness Heterogeneity
1 High-quality 6 [31,34,35,37,46,47] No significant Moderate
2 Aprotinin 11 [27-29,31-37,41] No significant Low
3 Gabexate mesilate 6 [42-44,46,47,49] No significant Low to moderate
4 Gabexate mesilate daily administrated dosage>900mg 5 [42,44,46,47,49] No significant Low to moderate
5 Gabexate mesilate daily administrated dosage>1500mg 2 [47,49] No significant Low to moderate
6 Trials with CMR≦0.10 7 [29,31-33,37,42,46] No significant Low to moderate
7 Trials with CMR>0.10 10 [27,28,34-36,41,43,46,47,49] No significant Low to moderate
8 Trials with CMR>0.20 2 [34,49] No significant Low to moderate
9 Trials with industrial support 9 [27,29,31,34,35,37,41-43] No significant Low to moderate
10 Trials with industrial support 8 [28,32,33,36,44,46] No significant Low to moderate
High-quality was defined as Jadad score>3 points; CMR control mortality rate.
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vention as outcomes. In the present analysis, we added
prevention of abdominal pain due to acute pancreatitis
and bowel obstruction. The present analysis had a larger
sample size of 1,697 in total, compared to 1,036 in the pre-
vious analysis. The effectiveness of protease inhibitors
stratified by CMR level was similarly examined in both
the previous and present analyses. In the previous analysis
[10], five [34,43,44,47,49] of 10 selected articles [31,33,
34,37,42-44,46,47,49] were with CMR >0.10 and showed
limited effectiveness. In the present analysis, 10 [27,28,
34-36,41,43,44,47,49] of 17 selected articles were with
CMR >0.10 and showed no significant effectiveness. On
the other hand, the subgroup analysis of articles withFigure 2 Pooled risk difference (RD) in acute pancreatitis in patients g
scores” of the individual trait. I2 value shown heterogeneity was 0%. 95% CCMR >0.20 [34,49] revealed a significant therapeutic ef-
fect. However, it is suspected that low-quality trials that
included potentially severe patients might have exagger-
ated the effectiveness. In fact, the mean Jadad score
was 2.5 in RCTs with CMR >0.20, and 1 point in those
with CMR >0.30, suggesting that it is very likely that
low-quality trials provided a veneer of effectiveness for
severe patients.
The quality of evidence was assessed for each trial by
two methods, one that used the conventional Jadad scor-
ing system, and the other based on the GRADE system.
The mean Jadad score (2.1 points) was low, and the ma-
jority of RCTs were deemed low to moderate quality, ex-
cept for six trials [31,34,35,37,46,47] that were deemediven protease inhibitors. The numbers in Parentheses are the “Jadad
I, 95% confidence interval.
Figure 3 Pooled risk difference (RD) in acute severe pancreatitis in patients given protease inhibitors. The numbers in Parentheses are
the “Jadad scores” of the individual trait. I2 value shown heterogeneity was 0%. 95% CI, 95% confidence interval.
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GRADE system to evaluate each RCT in terms of risk of
bias (random allocation, allocation concealment, blind-
ing, outcome data addressed, selective outcome report-
ing, and others). Furthermore, we graded the quality of
the body of evidence for each clinical outcome using the
GRADE system in addition to the Jadad scoring system
to further strengthen quality of evidence assessment.
Handling of outcome data was likely to become a nest of
bias, reporting bias, and ITT analysis were mentioned in
three articles [44,46,47], four articles [36,41,47,49], and
one article [47], respectively. The quality of RCTs in-
cluded in the present review was low in general, and
hence, the bodies of evidence and result estimations areFigure 4 Publication bias of trials reporting acute pancreatitis in patiboth likely to be low in quality. We also checked each
article in terms of whether there were descriptions re-
garding industrial support, tangible outcome, and sample
size calculation in the methodology. With respect to in-
dustrial support, we found no significant difference in ef-
fectiveness according to the status of industrial support;
however, eight articles [28,32,33,36,44,46,47,49] provided
no description regarding funding or medicine support,
and thus the actual status was unknown. With respect to
tangible outcomes, only four of 17 articles [36,41,47,49]
provided descriptions in the methods sections, and no
article reported the presence or absence of adverse
events. Sample size calculation was described in only
one article [47]. The CONSORT statement [51], whichents given protease inhibitors. RD, Risk Difference; SE, Standard Error.
Table 4 Sensitivity analysis for trial quality
No. of studies Pooled RD 95% CI
Overall 17 -0.02 -0.05 to 0.01
Jadad score ≧1 14 -0.02 -0.05 to 0.01
Jadad score ≧2 12 -0.01 -0.04 to 0.02
Jadad score ≧3 6 -0.02 -0.06 to 0.02
RD risk difference; CI confidence interval.
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size calculation, might have led to improved quality of
reporting [52,53], although previous studies found in-
appropriateness or deficit of reporting common in pub-
lished articles [54,55]. It was likely for the authors of
adopted trials to select only the preferable results to re-
port, among many outcomes measured.
This study has some limitations worth noting. First,
the subgroup analysis which aimed to consider disease
severity was not based on established criteria of severity.
Instead, we defined CMR >0.10 as an arbitrary and
retrospective index to indicate moderate to severe pan-
creatitis. Prospective indices such as the Atlanta Classifi-
cation [56], Ranson’s criteria [57], or APACHE-II score
[58] were used only in two RCTs [47,49]. Although
CMR is advantageous in that it can be easily calculated
after trial completion, clinical interpretation of case se-
verity based on CMR requires prudent consideration, as
it is subject to factors such as care quality provided at
each institution. Unfortunately, accurate evaluations of
the severity of acute pancreatitis are difficult at the entry
of each trial. With reluctance, the present study used
CMR as a surrogate measure of severity because only
two trials [34,49] had used either the Ranson’s score or
APACHE-II score.
The second limitation was the low quality of the indi-
vidual studies evaluated by our review. The overall mean
Jadad score was 2.1 (range, 0–5; three RCTs scored a 0
[28,32,43]), which meant that the overall quality of the
studies was low to moderate. Our previous meta-analysis
[10] showed that protease inhibitors were effective when
CMR was greater than 0.10, while this was true only
when CMR was greater than 0.20 in the present study.
In our previous report [10], we calculated the APACHE-
II scores using a multiple logistic equation described by
Knaus et al. [58]. We also found that CMR = 0.10 scoredTable 5 Sensitivity analysis for control mortality rate
No. of studies Pooled RD 95% CI
Overall 17 -0.02 -0.05 to 0.01
CMR ≧0.10 10 -0.03 -0.07 to 0.01
CMR ≧0.20 2 -0.19 -0.31 to -0.08
RD risk difference; CI confidence interval; CMR control mortality rate.roughly six points for the APACHE-II score method. On
the APACHE-II scale (highest score: 67 points), we dis-
covered that our patients scored 6 points when they pre-
sented with high-grade fever, hyperventilation, acidosis,
renal dysfunction, leukocytosis, and deterioration of
consciousness. One study has already validated the se-
verity of acute pancreatitis with the APACHE-II score
system [58]. CMR >0.20 for acute pancreatitis may be
worse than these physical conditions, and we would
be interested to test whether protease inhibitors would
be effective in preventing death or other complications.
Although meta-analyses of the two trials with CMR >0.20
showed that protease inhibitors were effective, reporting
quality and heterogeneity should be taken into account
when interpreting the results [34,49].
Third, the treatment modality of protease inhibitors was
confined to intravenous administration. The present study
excluded trials of intra-arterial or intra-abdominal infu-
sion of protease inhibitors because the main objective was
to update our previous meta-analysis [10]. Accordingly,
we did not evaluate the effectiveness of protease inhibi-
tors according to their various administrations. Further
systematic reviews and meta-analyses on these modal-
ities of administrations are expected in future. Future
RCTs in this field should examine the effectiveness of
protease inhibitors administered through intravenous
or intra-arterial infusion, particularly among patients
with severe acute pancreatitis.
Conclusions
This updated meta-analysis re-confirmed that there is
no solid evidence to support the use of intravenous pro-
tease inhibitors for preventing death, abdominal pain,
pseudocyst formation, intra-abdominal abscess forma-
tion, surgical intervention, bowel obstruction, or any
complications of pancreatitis excluding post-ERCP com-
plications. Future trials on the effectiveness of intraven-
ous protease inhibitor using established severity criteria
(i.e., APACHE-II score system) should be promoted, par-
ticularly for patients with severe acute pancreatitis.
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